CR8954A - POLYTHERAPY USING TRANSFERRINE FUSION PROTEINS INCLUDING GLP-1 - Google Patents

POLYTHERAPY USING TRANSFERRINE FUSION PROTEINS INCLUDING GLP-1

Info

Publication number
CR8954A
CR8954A CR8954A CR8954A CR8954A CR 8954 A CR8954 A CR 8954A CR 8954 A CR8954 A CR 8954A CR 8954 A CR8954 A CR 8954A CR 8954 A CR8954 A CR 8954A
Authority
CR
Costa Rica
Prior art keywords
fusion proteins
transferrine
polytherapy
proteins including
including glp
Prior art date
Application number
CR8954A
Other languages
Spanish (es)
Inventor
Sadeghi Homayoun
Prior Christopher
J Balance David
Original Assignee
Biorexis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorexis Pharmaceutical Corp filed Critical Biorexis Pharmaceutical Corp
Publication of CR8954A publication Critical patent/CR8954A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Optics & Photonics (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)

Abstract

La presente invencion suministra proteinas de fusion de transferina que incluyen peptidos terapeuticos o proteinas de uso terapeutico que son suceptibles a la ruptura con proteasa. La presente invencion suministra tambien proteinas de fusion de transferrina que incluyen peptidos o protinas de uso terapeutico que son sensibles, resistentes o parcialmente resistentes a la ruptura con proteasas.The present invention provides transferin fusion proteins that include therapeutic peptides or proteins for therapeutic use that are susceptible to protease breakdown. The present invention also provides transferrin fusion proteins that include peptides or protins of therapeutic use that are sensitive, resistant or partially resistant to breakage with proteases.

CR8954A 2004-08-03 2007-03-02 POLYTHERAPY USING TRANSFERRINE FUSION PROTEINS INCLUDING GLP-1 CR8954A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59803104P 2004-08-03 2004-08-03

Publications (1)

Publication Number Publication Date
CR8954A true CR8954A (en) 2007-10-02

Family

ID=35839920

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8954A CR8954A (en) 2004-08-03 2007-03-02 POLYTHERAPY USING TRANSFERRINE FUSION PROTEINS INCLUDING GLP-1

Country Status (19)

Country Link
EP (1) EP1814599A4 (en)
JP (1) JP2008509153A (en)
KR (1) KR20070085224A (en)
CN (1) CN101035568A (en)
AP (1) AP2007003920A0 (en)
AU (1) AU2005271403A1 (en)
BR (1) BRPI0514115A (en)
CA (1) CA2575756A1 (en)
CR (1) CR8954A (en)
EA (1) EA200700391A1 (en)
GB (1) GB2431583A (en)
IL (1) IL181108A0 (en)
MA (1) MA28843B1 (en)
MX (1) MX2007001424A (en)
NO (1) NO20071018L (en)
RU (1) RU2007107808A (en)
TN (1) TNSN07039A1 (en)
WO (1) WO2006017688A2 (en)
ZA (1) ZA200701484B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
EP1494732B1 (en) 2002-03-20 2008-01-30 MannKind Corporation Inhalation apparatus
DK1786784T3 (en) 2004-08-20 2011-02-14 Mannkind Corp Catalysis of diketopiperazine synthesis
CN104436170B (en) 2004-08-23 2018-02-23 曼金德公司 Diketopiperazine salt for drug delivery
EP1858546A4 (en) * 2005-03-04 2009-03-04 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
AU2006290227B2 (en) 2005-09-14 2012-08-02 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
KR20080096809A (en) 2006-02-22 2008-11-03 맨카인드 코포레이션 Method for Improving Pharmaceutical Properties of Microparticles Containing Diketopiperazine and Active Agents
EP2004238A2 (en) 2006-03-21 2008-12-24 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
KR101193722B1 (en) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 Exendin fusion proteins
WO2008033395A2 (en) * 2006-09-14 2008-03-20 Biorexis Pharmaceutical Corporation Melanocortin and transferrin fusion proteins
EP2195034A2 (en) 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
SG10201507036TA (en) 2008-06-13 2015-10-29 Mannkind Corp A dry powder inhaler and system for drug delivery
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (en) 2008-08-11 2018-02-11 曼凱公司 Ultra-fast use of insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
MX2011009512A (en) 2009-03-11 2011-11-29 Mannkind Corp Apparatus, system and method for measuring resistance of an inhaler.
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
IL223742A (en) 2010-06-21 2016-06-30 Mannkind Corp Dry powder inhaler and composition therefor
WO2012026526A1 (en) 2010-08-27 2012-03-01 国立大学法人宮崎大学 Hemokinin-1 receptor and hemokinin-1-derived peptide
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
RU2477726C1 (en) * 2011-10-18 2013-03-20 Общество С Ограниченной Ответственностью "Ньювак" (Ооо "Ньювак") Substituted phenoxyacetic acids, their esters and amides containing 2,6-dioxo-2,3,6,7-tetrahydro-1h-pyrin-8-yl fragments - a2a adenosine receptor antagonists and use thereof
HK1200318A1 (en) 2011-10-24 2015-08-07 曼金德公司 Methods and compositions for treating pain
CN103160565A (en) * 2011-12-09 2013-06-19 彩虹天健康科技研究(北京)有限责任公司 Research for influence on endocytosis of cell transferrins of UNC-51 kinase
WO2013162050A1 (en) * 2012-04-23 2013-10-31 株式会社Ｎｒｌファーマ Lactoferrin fusion protein and method for producing same
EP2872205B1 (en) 2012-07-12 2017-02-08 MannKind Corporation Dry powder drug delivery systems
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
JP2016506401A (en) 2012-12-21 2016-03-03 サノフイ Exendin-4 derivatives as dual GLP1 / GIP or three-way GLP1 / GIP / glucagon agonists
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CN103275177B (en) * 2013-06-24 2015-08-12 南京财经大学 There is the little peptide of feritin and ACE dual restraining activities, its preparation method and application
KR102465025B1 (en) 2013-07-18 2022-11-09 맨카인드 코포레이션 Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
TW201609796A (en) 2013-12-13 2016-03-16 賽諾菲公司 Non-acylated EXENDIN-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
FR3027395B1 (en) * 2014-10-17 2016-10-21 Biomerieux Sa COMPOSITION FOR IMMUNO-ENZYMATIC IMMUNOFLUORESCENCE ASSAY AND USES THEREOF
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
CN104645317B (en) * 2015-01-28 2020-04-17 中国科学院天津工业生物技术研究所 Application of polypeptide compound as polypeptide or protein drug carrier, method and fusion protein compound thereof
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US11041014B2 (en) 2016-10-28 2021-06-22 S & K Biopharma, Inc. Lactoferrin/albumin fusion protein and production method therefor
WO2019014552A1 (en) * 2017-07-14 2019-01-17 University Of Southern California Insulin-transferrin fusion protein and its prodrug, proinsulin-transferrin, for overcoming insulin resistance
EP3810186B1 (en) 2018-06-21 2022-09-28 Novo Nordisk A/S Novel compounds for treatment of obesity
CN110218259B (en) * 2019-06-24 2022-09-16 王跃驹 Application of fusion protein of glucagon-like peptide-1 short peptide and transferrin produced by plants in preparing oral hypoglycemic capsules
CN112661862B (en) * 2020-12-25 2023-03-31 深圳大学 Fusion protein and preparation method and application thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US7285526B2 (en) * 1995-07-14 2007-10-23 Meiogen Biotechnology Corporation Interferon antagonists useful for the treatment of interferon related diseases
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
WO2002021141A2 (en) * 2000-09-06 2002-03-14 Aventis Pharma S.A. Methods and compositions for diseases associated with amyloidosis
WO2004019872A2 (en) * 2002-08-30 2004-03-11 Biorexis Pharmaceutical Corporation Oral delivery of modified transferrin fusion proteins
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2003057200A2 (en) * 2002-01-11 2003-07-17 Novo Nordisk A/S Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains

Also Published As

Publication number Publication date
EP1814599A4 (en) 2008-12-17
JP2008509153A (en) 2008-03-27
EP1814599A2 (en) 2007-08-08
BRPI0514115A (en) 2008-05-27
AU2005271403A1 (en) 2006-02-16
GB2431583A (en) 2007-05-02
WO2006017688A3 (en) 2006-08-03
KR20070085224A (en) 2007-08-27
NO20071018L (en) 2007-04-11
MX2007001424A (en) 2008-03-13
AP2007003920A0 (en) 2007-02-28
WO2006017688A2 (en) 2006-02-16
CN101035568A (en) 2007-09-12
EA200700391A1 (en) 2007-10-26
MA28843B1 (en) 2007-09-03
GB0703685D0 (en) 2007-04-04
CA2575756A1 (en) 2006-02-16
IL181108A0 (en) 2007-07-04
ZA200701484B (en) 2008-07-30
TNSN07039A1 (en) 2008-06-02
RU2007107808A (en) 2008-09-10

Similar Documents

Publication Publication Date Title
EA200700210A1 (en) Fc OPTIONS
EP1699920A4 (en) Novel recombinant proteins with n-terminal free thiol
HUS1500024I1 (en) GLP-1 analogue fusion proteins
BRPI0518559A2 (en) motifs of the pancreatic polypeptide family, polypeptides and methods comprising the same
DE60121729D1 (en) Prion protein dimers for vaccinations
ATE482972T1 (en) TGF-BETA1 BINDING AND SUPPORTED PEPTIDES
BR0211623A (en) Peptide-based multimeric target contrast agents
CR8444A (en) IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
BRPI0514115A (en) combination therapy employing transferrin fusion proteins comprising glp-1
ATE542920T1 (en) MODIFIED HUMAN GROWTH HORMONE
DE60226724D1 (en) ANTIMICROBIAL POLYPEPTIDE
NO20061722L (en) New GLP-1 derivatives
CR20140465A (en) PROTEINS OF UNION TO INTERLEUQUINA-13
CR9637A (en) ILL-6 LINK PROTEINS
CR9223A (en) 18-METIL-19-NOR-17-PREGN-4-EN-21, 17-CARBOLACTONES, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
CL2008000910A1 (en) Fusion protein comprising a protein that cuts the beta amyloid peptide; pharmaceutical composition that includes it, and its use to prevent and / or treat diseases related to beta amyloid peptide.
BR0306905A (en) Flavivirus vaccines
DK1519944T3 (en) Methods for preparing fibrinogen
ATE491349T1 (en) NEW NUTRACEUTICS COMPOSITIONS
ATE501268T1 (en) DEVICES AND METHODS FOR DETERMINING PROTEASE ACTIVITY
GT200600361A (en) PEPTIDES AND COMPOUNDS FIXED TO A RECEIVER
DE50206480D1 (en) ANTIMICROBIAL PEPTIDE
EA200702193A1 (en) GLYCOSILIZATION BELKOV
ATE493432T1 (en) OBTAINING HEAT SHOCK PROTEINS
ATE452646T1 (en) COMPOSITIONS WITH EPIGALLOCATECHINGALLATE AND PROTEIN HYDROLYZATE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)